I took your advice and reached out to him. He said QSAM filed the IND a week before the PR came out, so they could be in Phase 1 next week. He also said "Cyclosam is the same drug as Lantheus' (NASDAQ: LNTH) FDA approved drug, Quadramet. QSAM filed its IND on Cyclosam for the treatment of bone cancer. Lantheus has FDA approval for the drug as a pain treatment for cancer patients." The two guys who's pictures are at the bottom of the management profile are the inventors. It sounds like QSAM and CycloSam could benefit kids with bone cancer.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.